Chemistry:Vicadrostat
Vicadrostat is also known by a number of code names; one of the best known is BI 690517. This is an experimental low-molecular-weight drug which acts as an inhibitor of aldosterone and cortisol synthesis and is proposed for use in combination with the SGLT2 inhibitor empagliflozin (is abbreviated to VicaEmpa) to treat people with type 2 diabetes,[1] high blood pressure,[2][3] cardiovascular disease[2] and kidney disease.[2][3][4]
Pharmacology
Pharmacodynamics
Vicadrostat is an aldosterone synthase inhibitor; Phase II clinical trials (involving 586 patients) have shown that a 10 mg dose of vicadrostat reduces the urinary albumin-to-creatinine ratio by approximately 40% compared with placebo; this effect is achieved both with and without concomitant use of an SGLT2 inhibitor (empagliflozin).[4][5][6]
References
- ↑ "Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus". Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders 8 (1): 33–53. February 2017. doi:10.1007/s13300-016-0211-x. PMID 27837465.
- ↑ 2.0 2.1 2.2 "Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors". Current Opinion in Nephrology and Hypertension 34 (3): 241–246. May 2025. doi:10.1097/MNH.0000000000001067. PMID 40012539.
- ↑ 3.0 3.1 "Aldosterone synthase inhibitors in hypertension and chronic kidney disease: double the benefit?". Current Opinion in Nephrology and Hypertension 35 (3): 337–346. May 2026. doi:10.1097/MNH.0000000000001175. PMID 41816811.
- ↑ 4.0 4.1 "Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD". European Journal of Endocrinology 194 (1): 46–57. January 2026. doi:10.1093/ejendo/lvaf265. PMID 41436034.
- ↑ "The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial". Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 40 (6): 1175–1186. May 2025. doi:10.1093/ndt/gfae263. PMID 39533115.
- ↑ "Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses". Diabetes, Obesity & Metabolism 28 (7): 6324–6333. July 2026. doi:10.1111/dom.70836. PMID 42086479.
 |  |
